New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:34 EDTABIOARCA Biopharma announces GENETIC-AF CTA accepted by Health Canada
ARCA biopharma announced that the company’s Clinical Trial Application for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in Q4. ARCA is evaluating Gencaro as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the U.S. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.
News For ABIO From The Last 14 Days
Check below for free stories on ABIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
08:04 EDTABIOLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use